EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023

Marie-Laure Chaix, Laura Terracol, Marie-Laure Nere, Karl Stefic iD, Caroline Lascoux-Combe, Victoria Manda, Pierre Sellier, Sarah Maylin iD, Jean-Michel Molina, Geoffroy Liegeon, Constance Delaugerre, Maud Salmona iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Marie-Laure Chaix und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de virologie, Hôpital Saint-Louis, APHP, Paris, France. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Antibodies, Neutralizing, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Surveillance studies of Transmitted Drug Resistance (TDR) are crucial in tracking the evolution of HIV epidemiology. Our aim was to investigate TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non‐nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), as well as to new drugs: lenacapavir, fostemsavir. Predictive sensitivity was evaluated for maraviroc and broadly neutralizing antibodies (bNAbs) (zinlirvimab and teropavimab). Between 2020 and 2023, 85 people with HIV (PWH) were diagnosed with primary HIV‐1 infection (PHI). Pol and env sequences were analyzed and TDR was characterized according to the French ANRS algorithm. The genotypic‐based prediction of bNAbs sensitivity was based on HIV env amino acid signatures I108, I201, F353 for teropavimab and N325, N332, H330 for zinlirvimab. TDR to NRTIs, NNRTIs, PIs and INIs was evidenced in 8.2%, 12.9%, 4.7%, and 5.9% strains, respectively. Ten viruses were CXCR4/dual mix. All viruses were susceptible to lenacapavir (100%) and 52% harbored resistance to fostemsavir. The genotypic profile was associated with a predictive positive value (PPV) > 83% of susceptibility to both teropavimab and zinlirvimab for 23 viruses (31%), while 22 (29%) had a PPV between 62% and 75%, suggesting reduced susceptibility to both bNAbs as soon as primary infection. The surveillance of TDR evidenced at the time of PHI is important with regard to new strategies for HIV patients with virological failure and global implementation of PrEP using NRTI, INI such as recently approved injectable cabotegravir, and future long‐acting drugs such as lenacapavir and bNAbs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Antibodies, NeutralizingAnti-HIV AgentsDrug Resistance, ViralHumansFranceMaleFemaleAdultMiddle AgedOrganophosphatesGenotypeHIV AntibodiesPiperazines

Stichwörter der Autor:innen

HIV‐1bNAbs (broadly neutralizing antibodiesdrug resistance mutationsfostemsavirlenacapavirprimary infectionteropavimabzinlirvimab

Substanzen

Antibodies, NeutralizingAnti-HIV AgentsfostemsavirOrganophosphatesHIV AntibodiesPiperazines

Autor:innen und Institutionen

  • Laboratoire de virologie, Hôpital Saint-Louis, APHP, Paris, France.
  • INSERM, U944, Université Paris Cité, Paris, France.
  • INSERM, U1259, Université de Tours, Tours, France.
  • Laboratoire de Virologie, Centre Hospitalier Régional Universitaire de Tours, Tours, France.
  • Department of Maladies Infectieuses, Hôpital Saint-Louis-Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France.
  • INSERM, U976 Team INSIGHT, Université Paris Cité, Paris, France.

ORCID-Profile: Karl Stefic, Sarah Maylin, Maud Salmona

Zitieren

APA

Chaix, M. L., Terracol, L., Nere, M. L., Stefic, K., Lascoux-Combe, C., Manda, V., Sellier, P., Maylin, S., Molina, J. M., Liegeon, G., Delaugerre, C., & Salmona, M. (2024). Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023. Journal of Medical Virology. https://doi.org/10.1002/jmv.29948

Vancouver

Chaix ML, Terracol L, Nere ML, Stefic K, Lascoux-Combe C, Manda V, et al. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023. Journal of Medical Virology. 2024. doi:10.1002/jmv.29948

BibTeX
@article{Chaix2024,
  author = {Chaix, Marie-Laure and Terracol, Laura and Nere, Marie-Laure and Stefic, Karl and Lascoux-Combe, Caroline and Manda, Victoria and Sellier, Pierre and Maylin, Sarah and Molina, Jean-Michel and Liegeon, Geoffroy and Delaugerre, Constance and Salmona, Maud},
  title = {Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29948}
}
Kostenlos starten →